Ipsen S.A. (OTCMKTS:IPSEY – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $30.11 and traded as high as $30.38. Ipsen shares last traded at $30.28, with a volume of 386 shares.
Ipsen Stock Performance
The stock’s 50 day moving average is $29.38 and its two-hundred day moving average is $30.12.
About Ipsen
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Featured Stories
- Five stocks we like better than Ipsen
- What is the FTSE 100 index?
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Why Invest in High-Yield Dividend Stocks?
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.